The new drug Rehart\u00ae has been included in public medical insurance (date: 2026-09-01), with a covered reimbursement price of 53,200,000 yen and an applicable category of C2 (new function \/ new technology). The impact on future performance has already been incorporated into the full-year consolidated earnings forecast, and if amendments are needed, they will be disclosed promptly.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4894","jir_company_name":"Quolips Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4894-20260901-01.pdf","jir_short_summary":"The new drug Rehart\u00ae has been included in public medical insurance (date: 2026-09-01), with a covered reimbursement price of 53,200,000 yen and an applicable category of C2 (new function \/ new technology). The impact on future performance has already been incorporated into the full-year consolidated earnings forecast, and if amendments are needed, they will be disclosed promptly.","jir_summary":"### Rehart\u00ae inclusion in insurance coverage\nThe public medical insurance coverage for Rehart\u00ae has been formally decided, and the insurance coverage date has been disclosed as September 1, 2026. The decision category is C2 (new function \/ new technology), and the reimbursement price is 53,200,000 yen. Regarding the impact on future performance, it is stated that this has already been incorporated into the full-year consolidated earnings forecast published on July 28, 2026, and any further revision will be disclosed promptly if necessary.\n\n### Outlook and disclosure policy\nThe impact on performance is already incorporated into the full-year consolidated earnings forecast, and if revisions are needed, rapid disclosure will be made. At present, no additional figures are provided. Uncertainties include the effect of insurance coverage implementation and market introduction.","jir_financial_highlights":"Insurance coverage date: 2026 \u5e74\uff19\u6708\uff11\u65e5 (Unknown)\nReimbursement price: 53,200,000 \u5186 (Unknown)\nDecision category: C\uff12\uff08new function \/ new technology\uff09 (Unknown)","jir_category":"","jir_hashtags":"#Rehart, #PublicMedicalInsuranceCoverage","jir_key_figures":"Insurance coverage date: 2026 \u5e74\uff19\u6708\uff11\u65e5\nReimbursement price: 53,200,000 \u5186\nDecision category: C\uff12\uff08new function \/ new technology\uff09","jir_meta_title":"\u3010Quolips Corporation\u3011Rehart\u00ae Insurance Coverage Announcement\uff5cSeptember 2026","jir_meta_description":"Rehart\u00ae approved for public medical insurance. Reimbursement price 53,200,000 yen, applicable category C2. Impact on full-year forecast already incorporated; will disclose if revisions occur.","jir_og_title":"\u3010Quolips Corporation\u3011Rehart\u00ae Insurance Coverage Announcement","jir_og_description":"Rehart\u00ae coverage under public medical insurance has been decided. Reimbursement price 53,200,000 yen, category C2. Future impact on performance already incorporated.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17194,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-109227","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n